Analyzing the Mutational Landscape of Prostate Cancer Susceptibility Genes through Next-Generation Sequencing (NGS) Analysis
DOI:
https://doi.org/10.62382/jcbt.v1i2.18Keywords:
Prostate Cancer, Next Generation Sequencing, MutationsAbstract
Prostate cancer, a significant public health concern, exhibits a complex genetic landscape influenced by a variety of susceptibility genes. This study deciphers the intricate genetic makeup of prostate cancer by examining mutations in 14 prostate cancer susceptibility genes. The Next-Generation Sequencing (NGS) approach was employed on a cohort of 45 prostate cancer patients to detect mutations. The gnomAD database was used to analyze mutational frequencies in the Asian population suffering from prostate cancer. The cBioPortal database was employed to check the presence of observed mutations in The Cancer Genome Atlas (TCGA) dataset. In addition, this study employed RT-qPCR and Immunohistochemistry (IHC) techniques were utilized to check the functional consequences of the observed pathogenic mutations. Finally, Metascape and DrugBank resources were used for gene enrichment and drug prediction analyses. Results of the NGS analysis revealed a total of 29 mutations (pathogenic and benign) within the examined prostate cancer cohort, distributed across four key genes (BRCA1/2, TP53, and PMS2) out of the total analyzed 14 genes. Pathogenic mutations in BRCA1/2 and TP53 genes are of particular interest due to their fundamental roles in DNA repair, cell cycle regulation, and tumor suppression. Functional consequence analyses (RT-qPCR and IHC) demonstrated the down-regulation of BRCA1/2 and TP53 genes in prostate cancer samples with pathogenic mutations, reinforcing the disruption of their tumor suppressor roles. Lastly, drug prediction analysis uncovered promising therapeutic options by identifying drugs capable of enhancing the mRNA expression of these genes. This opens new avenues for tailored treatment strategies aimed at restoring normal cellular functions of the BRCA1/2 and TP53 genes. In conclusion, this study provides a comprehensive view of genetic mutations in prostate cancer susceptibility genes, ranging from benign to pathogenic. It emphasizes the genetic complexity of prostate cancer and offers insights into potential mechanisms driving this malignancy. These findings lay the groundwork for further research, personalized treatment approaches, and enhanced clinical management of prostate cancer.
Downloads
References
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, et al. Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022, 27(17), 5730.
Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, et al. The molecular biology of prostate cancer: current understanding and clinical implications. Prostate cancer and prostatic diseases. 2017, 21(1), 22-36.
Elazab IM, El-Feky OA, Khedr EG, El-Ashmawy NE. Prostate cancer and the cell cycle: Focusing on the role of microRNAs. Gene. 2024, 928, 148785.
Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019, 10(2), 63-68.
Bedeschi M, Marino N, Cavassi E, Piccinini F, Tesei A. Cancer-associated fibroblast: role in prostate cancer progression to metastatic disease and therapeutic resistance. Cells. 2023, 12(5), 802.
Taylor RA, Risbridger GP. Prostatic tumor stroma: a key player in cancer progression. Current cancer drug targets. 2008, 8(6), 490-7.
Myers MB. Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Pharmacogenomics and Personalized Medicine. 2016, 9, 7-16.
Hameed Y, Ejaz S. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients. Journal of Cancer Research and Therapeutics. 2021, 17(4), 931-937.
Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU international. 2002, 90(2), 162-73.
James ND, Tannock I, N'Dow J, Feng F, Gillessen S, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. 2024, 403(10437), 1683-1722.
Usman M, Hameed Y. GNB1, a novel diagnostic and prognostic potential biomarker of head and neck and liver hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 2022.
Dong Y, Wu X, Xu C, Hameed Y, Abdel-Maksoud MA, et al. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures. Aging (Albany NY). 2024, 16(3), 2591-2616.
Hu H, Umair M, Khan SA, Sani AI, Iqbal S, et al. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. American Journal of Translational Research. 2024, 16(2), 432-445.
Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, et al. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. American Journal of Translational Research. 2024, 16(1), 63-74.
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, et al. Epidemiology and prevention of prostate cancer. European urology oncology. 2021, 4(6), 877-892.
Berenguer CV, Pereira F, Câmara JS, Pereira JA. Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. Current Oncology. 2023, 30(2), 2300-2321.
Brandão A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. International journal of molecular sciences. 2020, 21(14), 5036.
Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, et. al. BRCA mutations in prostate cancer: assessment, implications and treatment considerations. International journal of molecular sciences. 2021, 22(23), 12628.
Piccinin C, Panchal S, Watkins N, Kim RH. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Review of Anticancer Therapy. 2019, 19(9), 787-801.
Horackova K, Janatova M, Kleiblova P, Kleibl Z, Soukupova J. Early-onset ovarian cancer< 30 years: what do we know about its genetic predisposition? International journal of molecular sciences. 2023, 24(23), 17020.
Cozar J, Robles-Fernandez I, Martinez-Gonzalez L, Pascual-Geler M, Rodriguez-Martinez A, et al. Genetic markers a landscape in prostate cancer. Mutation Research/Reviews in Mutation Research. 2018, 775, 1-10.
Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Annals of oncology. 2023, 34(3), 215-227.
Vincent AT, Derome N, Boyle B, Culley AI, Charette SJ. Next-generation sequencing (NGS) in the microbiological world: How to make the most of your money. Journal of microbiological methods. 2017, 138, 60-71.
Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, et al. Variant interpretation using population databases: Lessons from gnomAD. Human Mutation. 2022, 43(8), 1012-1030.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012, 2(5), 401-4.
Wang L, Liu X, Yue M, Liu Z, Zhang Y, et al. Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database. Cancer Reports. 2022, 5(9), e1557.
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications. 2019, 10(1), 1523.
Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research. 2008 Jan, 36(Database issue), D901-6.
Vijayakumar S, Dhakshanamoorthy R, Baskaran A, Krishnan BS, Maddaly R. Drug resistance in human cancers-Mechanisms and implications. Life Sciences. 2024, 352, 122907.
Tung N, Lin NU, Kidd J, Allen BA, Singh N, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. Journal of clinical oncology. 2016, 34(13), 1460-8.
Kraus C, Hoyer J, Vasileiou G, Wunderle M, Lux MP, et al. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. International journal of cancer. 2017, 140(1), 95-102.
Sahin I, Saat H. New perspectives on the recurrent monoallelic germline mutations of DNA repair and checkpoint genes and clinical variability. Genetic Testing and Molecular Biomarkers. 2022, 26(1), 17-25.
Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes-Providing evidence of cancer predisposition genes. Gynecologic oncology. 2019, 153(2), 452-462.
Bono M, Fanale D, Incorvaia L, Cancelliere D, Fiorino A, et al. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: Looking over the hedge. ESMO open. 2021, 6(4), 100235.
LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genetics in Medicine. 2020, 22(2), 407-415.
Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014, 343(6178), 1470-5.
Raimundo L, Ramos H, Loureiro JB, Calheiros J, Saraiva L. BRCA1/P53: Two strengths in cancer chemoprevention. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020, 1873(1), 188339.
Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. Translational cancer research. 2016, 5(6), 650-663.
Rosen EM. BRCA1 in the DNA damage response and at telomeres. Frontiers in genetics. 2013, 4, 85.
Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nature reviews Molecular cell biology. 2010, 11(2), 138-48.
Zhang X, Li R. BRCA1-dependent transcriptional regulation: implication in tissue-specific tumor suppression. Cancers. 2018, 10(12), 513.
Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harbor perspectives in biology. 2015, 7(4), a016600.
Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003, 22(37), 5784-91.
Lim PX, Zaman M, Feng W, Jasin M. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. Molecular cell. 2024, 84(3), 447-462. e10.
Meireles Da Costa N, Palumbo A, De Martino M, Fusco A, Ribeiro Pinto LF, et al. Interplay between HMGA and TP53 in cell cycle control along tumor progression. Cellular and molecular life sciences. 2021, 78(3), 817-831.
Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochemical and biophysical research communications. 2010, 396(1), 85-9.
Song B, Yang P, Zhang S. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy. Cancer communications. 2024, 44(3), 297-360.
Mekonnen N, Yang H, Shin YK. Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors. Frontiers in Oncology. 2022, 12, 880643.
Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 2010, 31(6), 955-60.
Tufail M. DNA repair pathways in breast cancer: from mechanisms to clinical applications. Breast cancer research and treatment. 2023, 200(3), 305-321.
Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nature reviews Molecular cell biology. 2008, 9(4), 297-308.
Tarsounas M, Sung P. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. Nature reviews Molecular cell biology. 2020, 21(5), 284-299.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
